董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mette Kirstine Agger | 女 | Independent Director | 61 | 14.09万美元 | 4.20 | 2026-01-20 |
| Reinaldo Diaz | 男 | Independent Director | 72 | 14.09万美元 | 4.20 | 2026-01-20 |
| Steven Altschuler | 男 | Chairman of the Board | 72 | 16.34万美元 | 13.76 | 2026-01-20 |
| Brenda Cooperstone | 女 | Independent Director | 61 | 13.94万美元 | 7.78 | 2026-01-20 |
| R. Nolan Townsend | 男 | Director and Chief Executive Officer | 46 | 365.09万美元 | 106.43 | 2026-01-20 |
| Tolga Tanguler | -- | Independent Director | -- | 8.88万美元 | 1.20 | 2026-01-20 |
| Tim Van Hauwermeiren | -- | Independent Director | -- | 12.06万美元 | 1.20 | 2026-01-20 |
| Paula H.J. Cholmondeley | 女 | Independent Director | 79 | 14.10万美元 | 9.28 | 2026-01-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Nolan Townsend | 男 | Director and Chief Executive Officer | 46 | 365.09万美元 | 106.43 | 2026-01-20 |
| Jenny R. Robertson | 女 | Chief Legal Officer | 52 | 214.59万美元 | 27.48 | 2026-01-20 |
| Louis Tamayo | 男 | Chief Financial Officer | 50 | 166.59万美元 | 未持股 | 2026-01-20 |
| Jose Manuel Otero | -- | Chief Operating Officer | -- | 355.55万美元 | 未持股 | 2026-01-20 |
| Sandi See Tai | -- | Chief Development Officer | -- | 未披露 | 未持股 | 2026-01-20 |
| Narinder P. Bhalla | -- | Chief Medical Officer | -- | 未披露 | 未持股 | 2026-01-20 |
董事简历
中英对照 | 中文 | 英文- Mette Kirstine Agger
-
Mette Kirstine Agger自2016年1月以来一直担任我们的董事会成员。自2009年以来，Agger女士一直担任Lundbeckfonden Ventures的管理合伙人，该公司是一家生命科学风险基金，并与其关联公司一起持有超过5种我们有表决权的证券。在加入Lundbeckfonden Ventures之前，Agger女士于2000年共同创立了7TM A/S，这是一家从事治疗药物发现和开发的生物技术公司，并于2009年担任其首席执行官。在创立7TM之前，Agger女士是NeuroSearch A/S（一家药物研究与开发公司）管理团队的一员。阿格女士于2017年7月至2019年6月担任公共生命科学公司TreviTherapeutics，Inc.的董事会成员，并自2014年3月起担任生物制药公司Tiburio Therapeutics，Inc.的董事会成员，ScpharmaceuticalsInc.是一家公共制药公司，自2018年12月以来，以及自2010年4月以来在纳斯达克OMX哥本哈根公开交易的新兴专业制药公司Veloxis Pharmaceuticals A/S。她也任职于几个私人公司的董事会，包括Cydan II，Inc.，或Cydan。Agger女士获得了理学硕士学位。在哥本哈根大学（University of Copenhagen）获得生物学博士学位，并在雷丁大学（University of Reading）亨利商学院（Henley Business School）获得工商管理硕士学位。
Mette Kirstine Agger,has served as a member of Lexeo Therapeutics, Inc. board of directors since November 2020. Ms. Agger has served as Chief Executive Officer and Strategic Advisor of Ersum Biotech since March 2022. From 2009 to 2022, Ms. Agger served as a Senior Advisor and Managing Partner of Lundbeckfonden Biocapital (formerly Lundbeckfonden Ventures), a life sciences venture capital fund. Prior to joining Lundbeckfonden Biocapital, Ms. Agger co-founded 7TM A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its Chief Executive Officer from founding to 2009. Ms. Agger served on the board of Trevi Therapeutics, Inc., a public life sciences company, from July 2017 to June 2019 and Veloxis Pharmaceuticals A/S, a public pharmaceutical company from April 2010 to December 2019, and has served on the board of directors of Imara Inc., a public biopharmaceutical company from January 2016 to June 2020 and scPharmaceuticals Inc., a public pharmaceutical company, since March 2014. Ms. Agger received her M.Sc. in Biology from the University of Copenhagen and received her M.B.A. from Henley Business School at the University of Reading. - Mette Kirstine Agger自2016年1月以来一直担任我们的董事会成员。自2009年以来，Agger女士一直担任Lundbeckfonden Ventures的管理合伙人，该公司是一家生命科学风险基金，并与其关联公司一起持有超过5种我们有表决权的证券。在加入Lundbeckfonden Ventures之前，Agger女士于2000年共同创立了7TM A/S，这是一家从事治疗药物发现和开发的生物技术公司，并于2009年担任其首席执行官。在创立7TM之前，Agger女士是NeuroSearch A/S（一家药物研究与开发公司）管理团队的一员。阿格女士于2017年7月至2019年6月担任公共生命科学公司TreviTherapeutics，Inc.的董事会成员，并自2014年3月起担任生物制药公司Tiburio Therapeutics，Inc.的董事会成员，ScpharmaceuticalsInc.是一家公共制药公司，自2018年12月以来，以及自2010年4月以来在纳斯达克OMX哥本哈根公开交易的新兴专业制药公司Veloxis Pharmaceuticals A/S。她也任职于几个私人公司的董事会，包括Cydan II，Inc.，或Cydan。Agger女士获得了理学硕士学位。在哥本哈根大学（University of Copenhagen）获得生物学博士学位，并在雷丁大学（University of Reading）亨利商学院（Henley Business School）获得工商管理硕士学位。
- Mette Kirstine Agger,has served as a member of Lexeo Therapeutics, Inc. board of directors since November 2020. Ms. Agger has served as Chief Executive Officer and Strategic Advisor of Ersum Biotech since March 2022. From 2009 to 2022, Ms. Agger served as a Senior Advisor and Managing Partner of Lundbeckfonden Biocapital (formerly Lundbeckfonden Ventures), a life sciences venture capital fund. Prior to joining Lundbeckfonden Biocapital, Ms. Agger co-founded 7TM A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its Chief Executive Officer from founding to 2009. Ms. Agger served on the board of Trevi Therapeutics, Inc., a public life sciences company, from July 2017 to June 2019 and Veloxis Pharmaceuticals A/S, a public pharmaceutical company from April 2010 to December 2019, and has served on the board of directors of Imara Inc., a public biopharmaceutical company from January 2016 to June 2020 and scPharmaceuticals Inc., a public pharmaceutical company, since March 2014. Ms. Agger received her M.Sc. in Biology from the University of Copenhagen and received her M.B.A. from Henley Business School at the University of Reading.
- Reinaldo Diaz
-
Reinaldo Diaz自2017年1月以来一直担任我们的董事会成员。Diaz先生自2015年11月起担任专注于梦百合公司的风险投资公司Longitude Capital Management Co.，LLC的风险合伙人。Diaz自2005年起担任DA Advisors，LLC（一家专注于生物制药公司的金融和战略咨询公司）管理成员和董事总经理。Diaz先生于2008年至2018年担任私募股权公司Auven Therapeutics的董事总经理，该公司专注于生命科学。Diaz从1996年到2005年担任Diaz&Altschul Capital Management，LLC（一家专注于梦百合公司的资产管理公司）管理成员和联合创始人。Diaz先生从1993年到1996年担任Schroder Wertheim&Co.，Inc.的常务董事兼梦百合集团负责人。Diaz从1985年到1993年在PaineWebber Development Corporation担任多个职位，包括从1990年到1993年担任总裁。Diaz先生在哈佛大学（Harvard University）获得通识研究学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Reinaldo Diaz,has served as a member of Lexeo Therapeutics, Inc. board of directors since February 2022. Mr. Diaz has served as a Venture Partner at Longitude Capital, a healthcare venture capital firm since 2015, and he currently serves as the Chief Business Officer of Opna-Immuno Oncology, SA, a Longitude Capital portfolio company. Mr. Diaz has also served as a Managing Director of DA Advisors, LLC since 2005, providing strategic and financial advice primarily to life science companies. From 2008 to 2018, Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life science companies. From 1996 to 2005, Mr. Diaz served as a managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies. Prior to that, Mr. Diaz served as a managing director and head of the healthcare group at Schroder Wertheim & Co., Inc., and in various roles at PaineWebber Development Corporation, including as president. Mr. Diaz currently serves on the board of directors of the public pharmaceutical company, Inozyme Pharma, Inc. Mr. Diaz received a B.A. in General Studies from Harvard University and an M.B.A. from Harvard Business School. - Reinaldo Diaz自2017年1月以来一直担任我们的董事会成员。Diaz先生自2015年11月起担任专注于梦百合公司的风险投资公司Longitude Capital Management Co.，LLC的风险合伙人。Diaz自2005年起担任DA Advisors，LLC（一家专注于生物制药公司的金融和战略咨询公司）管理成员和董事总经理。Diaz先生于2008年至2018年担任私募股权公司Auven Therapeutics的董事总经理，该公司专注于生命科学。Diaz从1996年到2005年担任Diaz&Altschul Capital Management，LLC（一家专注于梦百合公司的资产管理公司）管理成员和联合创始人。Diaz先生从1993年到1996年担任Schroder Wertheim&Co.，Inc.的常务董事兼梦百合集团负责人。Diaz从1985年到1993年在PaineWebber Development Corporation担任多个职位，包括从1990年到1993年担任总裁。Diaz先生在哈佛大学（Harvard University）获得通识研究学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Reinaldo Diaz,has served as a member of Lexeo Therapeutics, Inc. board of directors since February 2022. Mr. Diaz has served as a Venture Partner at Longitude Capital, a healthcare venture capital firm since 2015, and he currently serves as the Chief Business Officer of Opna-Immuno Oncology, SA, a Longitude Capital portfolio company. Mr. Diaz has also served as a Managing Director of DA Advisors, LLC since 2005, providing strategic and financial advice primarily to life science companies. From 2008 to 2018, Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life science companies. From 1996 to 2005, Mr. Diaz served as a managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies. Prior to that, Mr. Diaz served as a managing director and head of the healthcare group at Schroder Wertheim & Co., Inc., and in various roles at PaineWebber Development Corporation, including as president. Mr. Diaz currently serves on the board of directors of the public pharmaceutical company, Inozyme Pharma, Inc. Mr. Diaz received a B.A. in General Studies from Harvard University and an M.B.A. from Harvard Business School.
- Steven Altschuler
-
Steven Altschuler，自2021年1月起担任Lexeo Therapeutics，Inc.董事会主席。Altschuler博士自2018年5月起担任私人投资公司Ziff Capital Partners的Healthcare Ventures董事总经理。他曾于2017年9月至2017年12月担任迈阿密大学医疗保健系统顾问，于2016年1月至2017年9月担任迈阿密大学医疗保健系统首席执行官和迈阿密大学医疗保健执行副总裁，并于2000年4月至2015年6月担任费城儿童医院首席执行官。在担任首席执行官之前，Altschuler博士曾在宾夕法尼亚大学CHOP和Perelman医学院担任多个职位，包括主任医师/儿科主任和胃肠病学、肝病学和营养科主任。Altschuler博士自2012年9月起担任WW国际公司董事，自2020年1月起担任Orchard Therapeutics公司董事，自2020年3月起担任89bio公司董事。他曾于2013年3月至2019年12月担任星火治疗公司董事会主席，并于2018年5月至2020年5月担任Adtalem Global教育公司董事。Altschuler博士在凯斯西储大学获得了数学学士学位和医学博士学位。
Steven Altschuler,has served as the Chairman of Lexeo Therapeutics, Inc. board of directors since January 2021. Dr. Altschuler has served as a Managing Director, Healthcare Ventures, of Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive Officer of the University of Miami Health Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children's Hospital of Philadelphia, or CHOP, from April 2000 until June 2015. Prior to assuming the role of Chief Executive Officer, Dr. Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including Physician-in-Chief/Chair of Pediatrics and chief of the Division of Gastroenterology, Hepatology and Nutrition. Dr. Altschuler has served as a director of WW International, Inc. since September 2012, as a director of Orchard Therapeutics plc since January 2020 and as a director of 89bio, Inc. since March 2020. He previously served as Chair of the board of directors of Spark Therapeutics, Inc. from March 2013 to December 2019 and as a director of Adtalem Global Education Inc. from May 2018 to May 2020. Dr. Altschuler received a B.A. in Mathematics and an M.D. from Case Western Reserve University. - Steven Altschuler，自2021年1月起担任Lexeo Therapeutics，Inc.董事会主席。Altschuler博士自2018年5月起担任私人投资公司Ziff Capital Partners的Healthcare Ventures董事总经理。他曾于2017年9月至2017年12月担任迈阿密大学医疗保健系统顾问，于2016年1月至2017年9月担任迈阿密大学医疗保健系统首席执行官和迈阿密大学医疗保健执行副总裁，并于2000年4月至2015年6月担任费城儿童医院首席执行官。在担任首席执行官之前，Altschuler博士曾在宾夕法尼亚大学CHOP和Perelman医学院担任多个职位，包括主任医师/儿科主任和胃肠病学、肝病学和营养科主任。Altschuler博士自2012年9月起担任WW国际公司董事，自2020年1月起担任Orchard Therapeutics公司董事，自2020年3月起担任89bio公司董事。他曾于2013年3月至2019年12月担任星火治疗公司董事会主席，并于2018年5月至2020年5月担任Adtalem Global教育公司董事。Altschuler博士在凯斯西储大学获得了数学学士学位和医学博士学位。
- Steven Altschuler,has served as the Chairman of Lexeo Therapeutics, Inc. board of directors since January 2021. Dr. Altschuler has served as a Managing Director, Healthcare Ventures, of Ziff Capital Partners, a private investment firm, since May 2018. He previously served as a consultant to the University of Miami Health Care System from September 2017 through December 2017, the Chief Executive Officer of the University of Miami Health Care System and Executive Vice President for Healthcare at the University of Miami from January 2016 to September 2017, and the Chief Executive Officer of The Children's Hospital of Philadelphia, or CHOP, from April 2000 until June 2015. Prior to assuming the role of Chief Executive Officer, Dr. Altschuler held several positions at CHOP and the Perelman School of Medicine at the University of Pennsylvania, including Physician-in-Chief/Chair of Pediatrics and chief of the Division of Gastroenterology, Hepatology and Nutrition. Dr. Altschuler has served as a director of WW International, Inc. since September 2012, as a director of Orchard Therapeutics plc since January 2020 and as a director of 89bio, Inc. since March 2020. He previously served as Chair of the board of directors of Spark Therapeutics, Inc. from March 2013 to December 2019 and as a director of Adtalem Global Education Inc. from May 2018 to May 2020. Dr. Altschuler received a B.A. in Mathematics and an M.D. from Case Western Reserve University.
- Brenda Cooperstone
-
Brenda Cooperstone，自2023年8月起担任Lexeo Therapeutics，Inc.董事会成员。库珀斯通博士曾在上市生物制药公司辉瑞公司（纽约证券交易所代码：PFE）担任多个领导职务，包括自2017年5月起担任高级副总裁，2016年5月至2022年12月担任全球产品开发中罕见病的首席开发官，2015年11月至2016年5月担任全球产品开发中罕见病的开发主管。库珀斯通博士自2019年10月起担任Senti Biosciences，Inc.董事会成员。库珀斯通博士于1999年在惠氏制药公司开始了她在制药行业的职业生涯，并于2009年加入辉瑞公司，当时该公司收购了惠氏制药公司。库珀斯通博士在麦吉尔大学获得了医学博士学位，并在蒙特利尔儿童医院完成了她的儿科住院医师实习，在费城儿童医院完成了她的儿科肾病学临床研究金，并在宾夕法尼亚大学的肾电解质部门完成了一个研究研究金。
Brenda Cooperstone has served as a member of Senti Biosciences Holdings, Inc.'s Board of Directors since October 2019. Dr. Cooperstone has held various leadership positions at Pfizer, Inc., a public biopharmaceutical company, including as Senior Vice President from May 2017 to December 2022, Chief Development Officer for Rare Disease in Global Product Development since May 2016 to December 2022, and Head of Development for Rare Disease in Global Product Development from November 2015 to May 2016. Dr. Cooperstone started her career in the pharmaceutical industry at Wyeth Pharmaceuticals Inc. in 1999 and joined Pfizer, Inc., when it acquired Wyeth Pharmaceuticals, Inc., in 2009. Dr. Cooperstone earned her M.D. from McGill University, and completed her residency in pediatrics at the Montreal Children's Hospital, her clinical fellowship in pediatric nephrology at Children's Hospital of Philadelphia and a research fellowship at the University of Pennsylvania's Renal Electrolyte division. - Brenda Cooperstone，自2023年8月起担任Lexeo Therapeutics，Inc.董事会成员。库珀斯通博士曾在上市生物制药公司辉瑞公司（纽约证券交易所代码：PFE）担任多个领导职务，包括自2017年5月起担任高级副总裁，2016年5月至2022年12月担任全球产品开发中罕见病的首席开发官，2015年11月至2016年5月担任全球产品开发中罕见病的开发主管。库珀斯通博士自2019年10月起担任Senti Biosciences，Inc.董事会成员。库珀斯通博士于1999年在惠氏制药公司开始了她在制药行业的职业生涯，并于2009年加入辉瑞公司，当时该公司收购了惠氏制药公司。库珀斯通博士在麦吉尔大学获得了医学博士学位，并在蒙特利尔儿童医院完成了她的儿科住院医师实习，在费城儿童医院完成了她的儿科肾病学临床研究金，并在宾夕法尼亚大学的肾电解质部门完成了一个研究研究金。
- Brenda Cooperstone has served as a member of Senti Biosciences Holdings, Inc.'s Board of Directors since October 2019. Dr. Cooperstone has held various leadership positions at Pfizer, Inc., a public biopharmaceutical company, including as Senior Vice President from May 2017 to December 2022, Chief Development Officer for Rare Disease in Global Product Development since May 2016 to December 2022, and Head of Development for Rare Disease in Global Product Development from November 2015 to May 2016. Dr. Cooperstone started her career in the pharmaceutical industry at Wyeth Pharmaceuticals Inc. in 1999 and joined Pfizer, Inc., when it acquired Wyeth Pharmaceuticals, Inc., in 2009. Dr. Cooperstone earned her M.D. from McGill University, and completed her residency in pediatrics at the Montreal Children's Hospital, her clinical fellowship in pediatric nephrology at Children's Hospital of Philadelphia and a research fellowship at the University of Pennsylvania's Renal Electrolyte division.
- R. Nolan Townsend
-
R. Nolan Townsend，自2020年1月起担任Lexeo Therapeutics，Inc.首席执行官和Lexeo Therapeutics，Inc.董事会成员。在加入Lexeo之前，汤森先生于2008年至2019年12月在全球制药公司辉瑞公司工作，在那里他担任了几个越来越重要的职务。最近，他担任辉瑞罕见病北美地区总裁。在担任这一职务期间，汤森先生负责监督该司的总体战略、跨职能组织和业务预算。汤森在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。Lexeo Therapeutics，Inc.董事会认为，Townsend先生有资格担任董事，因为他是Lexeo Therapeutics，Inc.的首席执行官，而且他在生物制药行业担任高管的经验丰富。
R. Nolan Townsend,has served as Lexeo Therapeutics, Inc. Chief Executive Officer and as a member of Lexeo Therapeutics, Inc. board of directors since January 2020. Before joining Lexeo, Mr. Townsend was at Pfizer Inc., a global pharmaceutical company, from 2008 to December 2019, where he held several roles of increasing responsibility. Most recently, he served as President, Pfizer Rare Disease for the North America region. In that role, Mr. Townsend was responsible for overseeing the division's overall strategy, cross functional organization and operating budget. Mr. Townsend received a B.A. in Economics from the University of Pennsylvania and an M.B.A. from the Harvard Business School. - R. Nolan Townsend，自2020年1月起担任Lexeo Therapeutics，Inc.首席执行官和Lexeo Therapeutics，Inc.董事会成员。在加入Lexeo之前，汤森先生于2008年至2019年12月在全球制药公司辉瑞公司工作，在那里他担任了几个越来越重要的职务。最近，他担任辉瑞罕见病北美地区总裁。在担任这一职务期间，汤森先生负责监督该司的总体战略、跨职能组织和业务预算。汤森在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。Lexeo Therapeutics，Inc.董事会认为，Townsend先生有资格担任董事，因为他是Lexeo Therapeutics，Inc.的首席执行官，而且他在生物制药行业担任高管的经验丰富。
- R. Nolan Townsend,has served as Lexeo Therapeutics, Inc. Chief Executive Officer and as a member of Lexeo Therapeutics, Inc. board of directors since January 2020. Before joining Lexeo, Mr. Townsend was at Pfizer Inc., a global pharmaceutical company, from 2008 to December 2019, where he held several roles of increasing responsibility. Most recently, he served as President, Pfizer Rare Disease for the North America region. In that role, Mr. Townsend was responsible for overseeing the division's overall strategy, cross functional organization and operating budget. Mr. Townsend received a B.A. in Economics from the University of Pennsylvania and an M.B.A. from the Harvard Business School.
- Tolga Tanguler
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Tim Van Hauwermeiren
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Paula H.J. Cholmondeley
-
Paula H.J. Cholmondeley， 从2004年到2009年担任战略策划私人顾问。从2000年4月到2004年1月她担任萨佩纸业特殊产品部（萨佩有限公司一个子公司）副总裁和总经理；从1998年1月到2000年4月她担任战略规划和并购私人顾问；从1992年到1998年1月她在欧文斯科宁担任多个管理职位，包括住宅绝缘总经理。她曾于1982年到1983年担任白宫高级人员以及远东地区多个国家美国贸易代表特别助理。她还在其他公司担任多个职位，包括西屋电梯有限公司管理职位、大费城蓝十字首席财务官和高级副总裁。她是国际互惠基金独立信托人并担任特雷克斯公司，奥伯尼国际和矿产技术公司董事。她从2004年6月到2010年6月担任Ultralife电池公司董事。
Paula H.J. Cholmondeley,is currently principal of The Sorrel Group, a consulting company founded by Ms. Cholmondeley in 2004 which focuses on corporate strategy and corporate governance matters. Ms. Cholmondeley served as Vice President and General Manager of Sappi Fine Paper, North America from 2000 through 2004, where she had profit and loss responsibility for their Specialty Products division. Ms. Cholmondeley held senior positions with various other companies from 1980 through 1998, including Owens Corning, The Faxon Company, Blue Cross of Greater Philadelphia, and Westinghouse Elevator Company, and also served as a White House Fellow assisting the U.S. Trade Representative during the Reagan administration. Ms. Cholmondeley, a former certified public accountant, is an alumnus of Howard University and received a Master's Degree in Accounting from the University of Pennsylvania, Wharton School of Finance. Ms. Cholmondeley is also a director at Bank OZK and Lexeo Therapeutics. Previously, Ms. Cholmondeley served as a director of Ultralife Corporation from 2004 through 2010, Albany International Corporation from 2005 to 2013, Minerals Technologies Inc. from 2005 to 2014, Dentsply International Inc. from 2001 to 2016, and Kapstone Paper and Packaging Corporation from 2016 to 2018 and an independent trustee of Nationwide Mutual Funds from 2000 to 2022. - Paula H.J. Cholmondeley， 从2004年到2009年担任战略策划私人顾问。从2000年4月到2004年1月她担任萨佩纸业特殊产品部（萨佩有限公司一个子公司）副总裁和总经理；从1998年1月到2000年4月她担任战略规划和并购私人顾问；从1992年到1998年1月她在欧文斯科宁担任多个管理职位，包括住宅绝缘总经理。她曾于1982年到1983年担任白宫高级人员以及远东地区多个国家美国贸易代表特别助理。她还在其他公司担任多个职位，包括西屋电梯有限公司管理职位、大费城蓝十字首席财务官和高级副总裁。她是国际互惠基金独立信托人并担任特雷克斯公司，奥伯尼国际和矿产技术公司董事。她从2004年6月到2010年6月担任Ultralife电池公司董事。
- Paula H.J. Cholmondeley,is currently principal of The Sorrel Group, a consulting company founded by Ms. Cholmondeley in 2004 which focuses on corporate strategy and corporate governance matters. Ms. Cholmondeley served as Vice President and General Manager of Sappi Fine Paper, North America from 2000 through 2004, where she had profit and loss responsibility for their Specialty Products division. Ms. Cholmondeley held senior positions with various other companies from 1980 through 1998, including Owens Corning, The Faxon Company, Blue Cross of Greater Philadelphia, and Westinghouse Elevator Company, and also served as a White House Fellow assisting the U.S. Trade Representative during the Reagan administration. Ms. Cholmondeley, a former certified public accountant, is an alumnus of Howard University and received a Master's Degree in Accounting from the University of Pennsylvania, Wharton School of Finance. Ms. Cholmondeley is also a director at Bank OZK and Lexeo Therapeutics. Previously, Ms. Cholmondeley served as a director of Ultralife Corporation from 2004 through 2010, Albany International Corporation from 2005 to 2013, Minerals Technologies Inc. from 2005 to 2014, Dentsply International Inc. from 2001 to 2016, and Kapstone Paper and Packaging Corporation from 2016 to 2018 and an independent trustee of Nationwide Mutual Funds from 2000 to 2022.
高管简历
中英对照 | 中文 | 英文- R. Nolan Townsend
R. Nolan Townsend，自2020年1月起担任Lexeo Therapeutics，Inc.首席执行官和Lexeo Therapeutics，Inc.董事会成员。在加入Lexeo之前，汤森先生于2008年至2019年12月在全球制药公司辉瑞公司工作，在那里他担任了几个越来越重要的职务。最近，他担任辉瑞罕见病北美地区总裁。在担任这一职务期间，汤森先生负责监督该司的总体战略、跨职能组织和业务预算。汤森在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。Lexeo Therapeutics，Inc.董事会认为，Townsend先生有资格担任董事，因为他是Lexeo Therapeutics，Inc.的首席执行官，而且他在生物制药行业担任高管的经验丰富。
R. Nolan Townsend,has served as Lexeo Therapeutics, Inc. Chief Executive Officer and as a member of Lexeo Therapeutics, Inc. board of directors since January 2020. Before joining Lexeo, Mr. Townsend was at Pfizer Inc., a global pharmaceutical company, from 2008 to December 2019, where he held several roles of increasing responsibility. Most recently, he served as President, Pfizer Rare Disease for the North America region. In that role, Mr. Townsend was responsible for overseeing the division's overall strategy, cross functional organization and operating budget. Mr. Townsend received a B.A. in Economics from the University of Pennsylvania and an M.B.A. from the Harvard Business School.- R. Nolan Townsend，自2020年1月起担任Lexeo Therapeutics，Inc.首席执行官和Lexeo Therapeutics，Inc.董事会成员。在加入Lexeo之前，汤森先生于2008年至2019年12月在全球制药公司辉瑞公司工作，在那里他担任了几个越来越重要的职务。最近，他担任辉瑞罕见病北美地区总裁。在担任这一职务期间，汤森先生负责监督该司的总体战略、跨职能组织和业务预算。汤森在宾夕法尼亚大学获得经济学学士学位，在哈佛商学院获得工商管理硕士学位。Lexeo Therapeutics，Inc.董事会认为，Townsend先生有资格担任董事，因为他是Lexeo Therapeutics，Inc.的首席执行官，而且他在生物制药行业担任高管的经验丰富。
- R. Nolan Townsend,has served as Lexeo Therapeutics, Inc. Chief Executive Officer and as a member of Lexeo Therapeutics, Inc. board of directors since January 2020. Before joining Lexeo, Mr. Townsend was at Pfizer Inc., a global pharmaceutical company, from 2008 to December 2019, where he held several roles of increasing responsibility. Most recently, he served as President, Pfizer Rare Disease for the North America region. In that role, Mr. Townsend was responsible for overseeing the division's overall strategy, cross functional organization and operating budget. Mr. Townsend received a B.A. in Economics from the University of Pennsylvania and an M.B.A. from the Harvard Business School.
- Jenny R. Robertson
Jenny R. Robertson，自2023年7月起担任Lexeo Therapeutics，Inc.首席法律和行政官。她曾于2022年3月至2022年12月担任Lexeo Therapeutics，Inc.总法律顾问和公司秘书，并于2023年1月至2023年6月担任高级副总裁、总法律顾问和人事主管。在2010年4月至2022年3月加入Lexeo之前，Robertson女士曾在全球制药公司辉瑞公司担任多个高级法律职务，最近担任辉瑞肿瘤业务部门副总裁兼首席法律顾问。在担任该职务之前，Robertson女士于2016年4月至2020年9月担任辉瑞罕见病业务部首席法律顾问。从2000年到2010年，罗伯逊女士在Hogan & Hartson LLP私人执业。罗伯逊女士在南伊利诺伊大学获得政治学学士学位，在乔治城大学法律中心获得法学博士学位。
Jenny R. Robertson,has served as Lexeo Therapeutics, Inc. Chief Legal and Administrative Officer since July 2023. She previously served as Lexeo Therapeutics, Inc. General Counsel and Company Secretary from March 2022 through December 2022 and as Senior Vice President, General Counsel and Head of People from January 2023 through June 2023. Before joining Lexeo, from April 2010 to March 2022, Ms. Robertson served in various senior legal roles at Pfizer Inc., a global pharmaceutical company, most recently as Vice President and Chief Counsel to Pfizer's Oncology Business Unit. Prior to that role, Ms. Robertson served as Chief Counsel for Pfizer's Rare Disease Business Unit from April 2016 to September 2020. From 2000 to 2010, Ms. Robertson was in private practice with Hogan & Hartson LLP. Ms. Robertson received a B.A. in Political Science from Southern Illinois University and a J.D. from the Georgetown University Law Center.- Jenny R. Robertson，自2023年7月起担任Lexeo Therapeutics，Inc.首席法律和行政官。她曾于2022年3月至2022年12月担任Lexeo Therapeutics，Inc.总法律顾问和公司秘书，并于2023年1月至2023年6月担任高级副总裁、总法律顾问和人事主管。在2010年4月至2022年3月加入Lexeo之前，Robertson女士曾在全球制药公司辉瑞公司担任多个高级法律职务，最近担任辉瑞肿瘤业务部门副总裁兼首席法律顾问。在担任该职务之前，Robertson女士于2016年4月至2020年9月担任辉瑞罕见病业务部首席法律顾问。从2000年到2010年，罗伯逊女士在Hogan & Hartson LLP私人执业。罗伯逊女士在南伊利诺伊大学获得政治学学士学位，在乔治城大学法律中心获得法学博士学位。
- Jenny R. Robertson,has served as Lexeo Therapeutics, Inc. Chief Legal and Administrative Officer since July 2023. She previously served as Lexeo Therapeutics, Inc. General Counsel and Company Secretary from March 2022 through December 2022 and as Senior Vice President, General Counsel and Head of People from January 2023 through June 2023. Before joining Lexeo, from April 2010 to March 2022, Ms. Robertson served in various senior legal roles at Pfizer Inc., a global pharmaceutical company, most recently as Vice President and Chief Counsel to Pfizer's Oncology Business Unit. Prior to that role, Ms. Robertson served as Chief Counsel for Pfizer's Rare Disease Business Unit from April 2016 to September 2020. From 2000 to 2010, Ms. Robertson was in private practice with Hogan & Hartson LLP. Ms. Robertson received a B.A. in Political Science from Southern Illinois University and a J.D. from the Georgetown University Law Center.
- Louis Tamayo
Louis Tamayo，从2023年2月到2024年9月担任Siemens Healthineers AG的高级副总裁，负责卓越运营。从2020年10月到2023年2月，他还担任Siemens Healthineers AG的高级副总裁兼产品特许经营财务主管。从2016年到2020年10月，Tamayo先生担任Siemens Healthineers AG的副总裁兼研发财务主管（产品生命周期管理）。从2014年到2016年，Tamayo先生担任Becton， Dickinson and Company的业务部门副总裁兼首席财务官，负责糖尿病护理。从2000年到2014年，Tamayo先生曾在Pfizer担任各种高级领导职务，包括战略和分析区域主管高级总监，美国初级保健区域财务总监和亚太金融项目办公室主任。Tamayo先生持有Northeastern 大学金融和市场营销工商管理硕士学位。
Louis Tamayo served as Senior Vice President of Siemens Healthineers AG from February 2023 to September 2024, responsible for Operations Excellence. From October 2020 to February 2023, he also served as Senior Vice President and Product Franchise Finance Director of Siemens Healthineers AG. From 2016 to October 2020, Mr. Tamayo served as Vice President and Head of R&D Finance (Product Lifecycle Management) of Siemens Healthineers AG. From 2014 to 2016, Mr. Tamayo served as the Vice President and Chief Financial Officer of the business unit of Becton, Dickinson and Company, responsible for diabetes care. From 2000 to 2014, Mr. Tamayo held various senior leadership positions at Pfizer, including Senior Director of Strategy and Analytics, Regional Finance Director of Primary Care in the United States, and Director of the Asia-Pacific Financial Program Office. Mr. Tamayo holds an MBA degree in Finance and Marketing from Northeastern University.- Louis Tamayo，从2023年2月到2024年9月担任Siemens Healthineers AG的高级副总裁，负责卓越运营。从2020年10月到2023年2月，他还担任Siemens Healthineers AG的高级副总裁兼产品特许经营财务主管。从2016年到2020年10月，Tamayo先生担任Siemens Healthineers AG的副总裁兼研发财务主管（产品生命周期管理）。从2014年到2016年，Tamayo先生担任Becton， Dickinson and Company的业务部门副总裁兼首席财务官，负责糖尿病护理。从2000年到2014年，Tamayo先生曾在Pfizer担任各种高级领导职务，包括战略和分析区域主管高级总监，美国初级保健区域财务总监和亚太金融项目办公室主任。Tamayo先生持有Northeastern 大学金融和市场营销工商管理硕士学位。
- Louis Tamayo served as Senior Vice President of Siemens Healthineers AG from February 2023 to September 2024, responsible for Operations Excellence. From October 2020 to February 2023, he also served as Senior Vice President and Product Franchise Finance Director of Siemens Healthineers AG. From 2016 to October 2020, Mr. Tamayo served as Vice President and Head of R&D Finance (Product Lifecycle Management) of Siemens Healthineers AG. From 2014 to 2016, Mr. Tamayo served as the Vice President and Chief Financial Officer of the business unit of Becton, Dickinson and Company, responsible for diabetes care. From 2000 to 2014, Mr. Tamayo held various senior leadership positions at Pfizer, including Senior Director of Strategy and Analytics, Regional Finance Director of Primary Care in the United States, and Director of the Asia-Pacific Financial Program Office. Mr. Tamayo holds an MBA degree in Finance and Marketing from Northeastern University.
- Jose Manuel Otero
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Sandi See Tai
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Narinder P. Bhalla
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介